96. Crohn disease Clinical trials / Disease details
Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2017-002545-30-GB (EUCTR) | 06/11/2017 | 07/06/2018 | Controlled trial to assess low intensity autologous stem cell transplant in refractory Crohn's Disease | Autologous Stem cell Transplantation In refractory Crohn's disease - Low Intensity Therapy Evaluation - ASTIClite | Refractory Crohn's Disease MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Trade Name: Cyclophosphamide Product Name: Cyclophosphamide INN or Proposed INN: Cyclophosphamide monohydrate INN or Proposed INN: Cyclophosphamide monohydrate Trade Name: Filgrastim Product Name: Filgrastim INN or Proposed INN: Filgrastim Trade Name: Fludarabine Product Name: Fludarabine INN or Proposed INN: Fludarabine phosphate Trade Name: Thymoglobuline Product Name: Thymoglobuline INN or Proposed INN: Rabbit anti-human thymocyte immunoglobulin | Barts Health NHS Trust | NULL | Not Recruiting | Female: yes Male: yes | 99 | Phase 3 | United Kingdom | ||
| 2 | NCT00692939 (ClinicalTrials.gov) | June 26, 2012 | 3/6/2008 | Autologous Stem Cell Transplantation for Crohn's Disease | Autologous Stem Cell Transplantation With CD34-Selected Peripheral Blood Stem Cells (PBSC) in Pediatric and Adult Patients With Severe Crohn's Disease | Crohn's Disease | Biological: autologous CD34-selected peripheral blood stem cells transplant;Drug: Alemtuzumab;Drug: ATG;Drug: Melphalan;Drug: Thiotepa;Drug: Rituximab;Drug: Cyclophosphamide;Drug: G-CSF;Drug: Mesna | Paul Szabolcs | NULL | Recruiting | 10 Years | 60 Years | All | 20 | Phase 1/Phase 2 | United States |
| 3 | EUCTR2005-003337-40-IT (EUCTR) | 19/11/2007 | 30/12/2008 | Autologous Stem Cell Transplantation for Crohn?s Disease: Autologous Stem Cell Transplantation International Crohn?s Disease Trial A multicentre, prospective, randomised phase III study conducted by the European Crohn?s and Colitis Organisation (ECCO), sponsored by the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation (EBMT) - ASTIC | Autologous Stem Cell Transplantation for Crohn?s Disease: Autologous Stem Cell Transplantation International Crohn?s Disease Trial A multicentre, prospective, randomised phase III study conducted by the European Crohn?s and Colitis Organisation (ECCO), sponsored by the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation (EBMT) - ASTIC | Crohn`s disease MedDRA version: 9.1;Level: LLT;Classification code 10013099;Term: Disease Crohns | Trade Name: ENDOXAN BAXTER INN or Proposed INN: Cyclophosphamide Trade Name: THYMOGLOBULINE INN or Proposed INN: Antithymocyte immunoglobulin (rabbit) | WOLFSON DIGESTIVE DISEASES CENTRE | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 48 | Phase 3 | United Kingdom;Italy | ||
| 4 | EUCTR2005-003337-40-GB (EUCTR) | 13/02/2006 | 13/01/2006 | Autologous Stem Cell Transplantation for Crohn's Disease ('ASTIC'-Trial: Autologous Stem Cell Transplantation International Crohn's Disease Trial) - ASTIC | Autologous Stem Cell Transplantation for Crohn's Disease ('ASTIC'-Trial: Autologous Stem Cell Transplantation International Crohn's Disease Trial) - ASTIC | Patients with Crohn's disease who have not responded to immunosupressant medication | Product Name: Cyclophosphamide Product Code: N/A INN or Proposed INN: cyclophosphamide Other descriptive name: N/A INN or Proposed INN: cyclophosphamide Other descriptive name: N/A Product Name: Filgrastim Product Code: N/A INN or Proposed INN: Filgrastim Other descriptive name: N/A Product Name: rabbit antithymocyte globulin Product Code: rbATG INN or Proposed INN: rabbit antithymocyte globulin Other descriptive name: N/A Product Name: Mesna Product Code: N/A INN or Proposed INN: mensa Other descriptive name: N/A Product Name: methyl prednisolone Product Code: N/A INN or Proposed INN: methyl prednisolone Other descriptive name: N/A Product Name: ciprofloxacin Product Code: N/A INN or Proposed INN: ciprofloxacin Other descriptive name: N/A | European Group for Blood and Marrow Transplantation (EMBT) | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 48 | United Kingdom | |||
| 5 | NCT00271947 (ClinicalTrials.gov) | April 2005 | 2/1/2006 | Crohn's Disease Stem Cell Transplantation | Crohn's Disease Non-myeloablative Autologous Hematopoietic Stem Cell Transplantation (CDNST) Versus Standard Therapy | Crohn's Disease | Biological: Autologous Stem Cell Transplantation | Northwestern University | NULL | Terminated | 18 Years | 55 Years | All | 1 | Phase 2 | United States |